Abstract | OBJECTIVES: BACKGROUND: METHODS: Twenty-three patients with clinically well-defined atherosclerosis and isolated hypoalphalipoproteinemia were prospectively randomized to receive gemfibrozil, NA or combination therapy in an open-label, crossover design trial to assess the effects on serum lipids. Lipid profiles and other relevant laboratory variables were monitored while the patients were on and off pharmacologic lipid-modulating therapy. RESULTS: In those 14 patients able to tolerate all forms of pharmacotherapy, HDL-C of 0.89 +/- 0.17 mmol/liter (34.5 +/- 6.5 mg/dl) increased by 15%, to 1.02 +/- 0.18 mmol/liter (39.7 +/- 7.1 mg/dl), while taking gemfibrozil (1,200 mg/day); by 35%, to 1.20 +/- 0.21 mmol/liter (46.5 +/- 8.1 mg/dl), while taking NA (mean dose 2,250 mg/day); and by 45%, to 1.29 +/- 0.19 mmol/liter (50.0 +/- 7.5 mg/dl), while taking combination therapy of gemfibrozil plus NA (p < 0.001 for all interventions as compared with baseline/washout; p < 0.005 NA vs. gemfibrozil; p < 0.001 combination therapy vs. gemfibrozil alone; p = 0.088 combination therapy vs. NA alone). Statistically significant favorable alterations were also observed with low density lipoprotein cholesterol ( LDL-C), LDL-C/HDL-C, non-HDL-C/HDL-C, apolipoprotein ( Apo) B and Apo B/ Apo A1. CONCLUSIONS: In the majority of patients with clinical atherosclerotic disease and isolated hypoalphalipoproteinemia, pharmacologic therapy to raise HDL-C is not only feasible but is also effective with currently available agents, particularly when used in combination.
|
Authors | M J Zema |
Journal | Journal of the American College of Cardiology
(J Am Coll Cardiol)
Vol. 35
Issue 3
Pg. 640-6
(Mar 01 2000)
ISSN: 0735-1097 [Print] United States |
PMID | 10716466
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Cholesterol, HDL
- Cholesterol, LDL
- Hypolipidemic Agents
- Niacin
- Gemfibrozil
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Arteriosclerosis
(blood, drug therapy)
- Cholesterol, HDL
(blood)
- Cholesterol, LDL
(blood)
- Cross-Over Studies
- Drug Therapy, Combination
- Female
- Gemfibrozil
(therapeutic use)
- Humans
- Hypolipidemic Agents
(therapeutic use)
- Hypolipoproteinemias
(blood, drug therapy)
- Male
- Middle Aged
- Niacin
(therapeutic use)
- Prospective Studies
- Treatment Outcome
|